Investigating how Neuromedin-U affects bone formation
Official title: NMUR2 in bone formation
Funded at Marian University · NIH-10889546 · Data updated 2026-11-12
This study is looking at how a molecule called Neuromedin-U affects bone growth, with the hope of finding new ways to treat osteoporosis, a condition that makes bones weak and more likely to break.
Quick facts
| Grant type | R03 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Marian University NIH-funded |
| Lab location | 1 site (Indianapolis, United States) |
| Project start | May 15, 2024 |
| Project end | April 30, 2026 |
| Funding year | 2024 |
| Award (this year) | $130,600 |
| NIH project number | 1R03AG081947-01A1 |
| Project ID | NIH-10889546 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals at risk for osteoporosis, particularly postmenopausal women and older adults.
✕Less likely to help
Patients who do not have osteoporosis or are not at risk for bone density loss may not benefit from this research.
What this research studies
This research aims to understand the molecular pathway through which Neuromedin-U (NMU) negatively regulates bone formation. By studying this pathway in mice, the researchers hope to identify NMU Receptor 2 (NMUR2) as a potential target for new treatments for osteoporosis. Osteoporosis is a serious condition that increases the risk of fractures and disability, and current treatment options are limited. The study will explore how NMU affects bone cells, which could lead to innovative therapies for managing this chronic disease.
Why it matters
Potential benefit: If successful, this research could lead to new treatments for osteoporosis, improving bone health and reducing fracture risk for patients.
How similar studies have gone: Previous research has shown that targeting similar molecular pathways can lead to advancements in osteoporosis treatment, indicating potential for success in this novel approach.
Where this research is happening
-
Marian University
Indianapolis, United States Active
Researchers
- Principal investigator: Lowery, Jonathan Wayne — Marian University
- Study coordinator: Lowery, Jonathan Wayne
Related research
Other NIH-funded projects on the same topics.
-
How a small chemical tag (lysine methylation) controls an HPV protein called E2
Looks at whether a tiny chemical tag on the HPV E2 protein changes how the virus copies itself and controls genes, which matters for people with high-risk HPV infections.
-
Exploring how chlamydia may increase the risk of cervical cancer linked to HPV infections
This study is looking at how infections with Chlamydia and HPV might work together to increase the risk of cervical cancer, and it aims to find out how this happens so that we can improve ways to prevent and treat the disease.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.